APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Antinematode Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Antinematode Drugs Industry Growth and Trends Forecast to 2032

Report ID 173966450127 December 2025122 pages

Choose your research edition.

Industry ResearchAntinematode Drugs Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Antinematode Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Antinematode Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antinematode Drugs Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Antinematode Drugs Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Antinematode Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Antinematode Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Antinematode Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antinematode Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antinematode Drugs include Zhejiang Anbet Pharmaceutical Co., Ltd., Sichuan Tiande Pharmaceutical Co., Ltd., Shaoxing Minsheng Pharmaceutical Co., Ltd., Shanghai Tengrui Pharmaceutical Co., Ltd., Shanghai SPH Xinyi Pharmaceutical Co., Ltd., Shaanxi Hanwang Pharmaceutical Co., Ltd., Jiaozuo Furuitang Pharmaceutical Co., Ltd., China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. and Hubei Ruihua Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Antinematode Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Antinematode Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Antinematode Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Antinematode Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Antinematode Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Antinematode Drugs Market by Company

Zhejiang Anbet Pharmaceutical Co., Ltd.

Sichuan Tiande Pharmaceutical Co., Ltd.

Shaoxing Minsheng Pharmaceutical Co., Ltd.

Shanghai Tengrui Pharmaceutical Co., Ltd.

Shanghai SPH Xinyi Pharmaceutical Co., Ltd.

Shaanxi Hanwang Pharmaceutical Co., Ltd.

Jiaozuo Furuitang Pharmaceutical Co., Ltd.

China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd.

Hubei Ruihua Pharmaceutical Co., Ltd.

Guilin Nanyao Pharmaceutical Co., Ltd.

Fujian Dongrui Pharmaceutical Co., Ltd.

Diao Group Chengdu Pharmaceutical Co., Ltd.

Chengdu Hengda Pharmaceutical Co., Ltd.

Beijing Taiyang Pharmaceutical Co., Ltd.

Anhui Shengying Pharmaceutical Co., Ltd.

Sequent Scientific

Salius Pharma

Lasa Supergenerics Limited

K.A. Malle Pharmaceuticals

Johnson & Johnson

GlaxoSmithKline

Fredun Pharmaceuticals Ltd

Esteve Pharmaceuticals

Eipico

Cadila Pharmaceuticals

Amneal Pharmaceuticals

Antinematode Drugs Segment by Type

Albendazole

Mebendazole

Piperazine

Pyrantel Pamoate

Others

Antinematode Drugs Segment by Application

For Veterinary Use

For Human Use

Antinematode Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antinematode Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antinematode Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antinematode Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antinematode Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Antinematode Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Albendazole Table 2. Major Company of Mebendazole Table 3. Major Company of Piperazine Table 4. Major Company of Pyrantel Pamoate Table 5. Major Company of Others Table 6. Global Antinematode Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Antinematode Drugs Sales by Type (2021-2026) & (K Units) Table 8. Global Antinematode Drugs Sales Market Share in Volume by Type (2021-2026) Table 9. Global Antinematode Drugs Sales by Type (2021-2026) & (US$ Million) Table 10. Global Antinematode Drugs Sales Market Share in Value by Type (2021-2026) Table 11. Global Antinematode Drugs Price by Type (2021-2026) & (US$/Unit) Table 12. Global Antinematode Drugs Sales by Type (2027-2032) & (K Units) Table 13. Global Antinematode Drugs Sales Market Share in Volume by Type (2027-2032) Table 14. Global Antinematode Drugs Sales by Type (2027-2032) & (US$ Million) Table 15. Global Antinematode Drugs Sales Market Share in Value by Type (2027-2032) Table 16. Global Antinematode Drugs Price by Type (2027-2032) & (US$/Unit) Table 17. North America Antinematode Drugs Sales by Type (2021-2026) & (K Units) Table 18. North America Antinematode Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Antinematode Drugs Sales by Type (2021-2026) & (K Units) Table 20. Europe Antinematode Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Antinematode Drugs Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific Antinematode Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Antinematode Drugs Sales by Type (2021-2026) & (K Units) Table 24. Latin America Antinematode Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Antinematode Drugs Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa Antinematode Drugs Sales by Type (2021-2026) & (US$ Million) Table 27. Antinematode Drugs Industry Trends Table 28. Antinematode Drugs Industry Drivers Table 29. Antinematode Drugs Industry Opportunities and Challenges Table 30. Antinematode Drugs Industry Restraints Table 31. Global Antinematode Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Antinematode Drugs Revenue Market Share by Company (2021-2026) Table 33. Global Antinematode Drugs Sales by Company (2021-2026) & (K Units) Table 34. Global Antinematode Drugs Sales Share by Company (2021-2026) Table 35. Global Antinematode Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global Antinematode Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Antinematode Drugs Major Company Production Sites and Headquarters Table 38. Global Antinematode Drugs Company, Product Type & Application Table 39. Global Antinematode Drugs Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Antinematode Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Antinematode Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Antinematode Drugs Sales by Region (2021-2026) & (K Units) Table 44. Global Antinematode Drugs Sales Market Share in Volume by Region (2021-2026) Table 45. Global Antinematode Drugs Sales by Region (2021-2026) & (US$ Million) Table 46. Global Antinematode Drugs Sales Market Share in Value by Region (2021-2026) Table 47. Global Antinematode Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global Antinematode Drugs Sales by Region (2027-2032) & (K Units) Table 49. Global Antinematode Drugs Sales Market Share in Volume by Region (2027-2032) Table 50. Global Antinematode Drugs Sales by Region (2027-2032) & (US$ Million) Table 51. Global Antinematode Drugs Sales Market Share in Value by Region (2027-2032) Table 52. Global Antinematode Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global Antinematode Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Antinematode Drugs Sales by Application (2021-2026) & (K Units) Table 55. Global Antinematode Drugs Sales Market Share in Volume by Application (2021-2026) Table 56. Global Antinematode Drugs Sales by Application (2021-2026) & (US$ Million) Table 57. Global Antinematode Drugs Sales Market Share in Value by Application (2021-2026) Table 58. Global Antinematode Drugs Price by Application (2021-2026) & (US$/Unit) Table 59. Global Antinematode Drugs Sales by Application (2027-2032) & (K Units) Table 60. Global Antinematode Drugs Sales Market Share in Volume by Application (2027-2032) Table 61. Global Antinematode Drugs Sales by Application (2027-2032) & (US$ Million) Table 62. Global Antinematode Drugs Sales Market Share in Value by Application (2027-2032) Table 63. Global Antinematode Drugs Price by Application (2027-2032) & (US$/Unit) Table 64. North America Antinematode Drugs Sales by Application (2021-2026) & (K Units) Table 65. North America Antinematode Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Antinematode Drugs Sales by Application (2021-2026) & (K Units) Table 67. Europe Antinematode Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Antinematode Drugs Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific Antinematode Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Antinematode Drugs Sales by Application (2021-2026) & (K Units) Table 71. Latin America Antinematode Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Antinematode Drugs Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa Antinematode Drugs Sales by Application (2021-2026) & (US$ Million) Table 74. Zhejiang Anbet Pharmaceutical Co., Ltd. Company Information Table 75. Zhejiang Anbet Pharmaceutical Co., Ltd. Business Overview Table 76. Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 78. Zhejiang Anbet Pharmaceutical Co., Ltd. Recent Development Table 79. Sichuan Tiande Pharmaceutical Co., Ltd. Company Information Table 80. Sichuan Tiande Pharmaceutical Co., Ltd. Business Overview Table 81. Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 83. Sichuan Tiande Pharmaceutical Co., Ltd. Recent Development Table 84. Shaoxing Minsheng Pharmaceutical Co., Ltd. Company Information Table 85. Shaoxing Minsheng Pharmaceutical Co., Ltd. Business Overview Table 86. Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 88. Shaoxing Minsheng Pharmaceutical Co., Ltd. Recent Development Table 89. Shanghai Tengrui Pharmaceutical Co., Ltd. Company Information Table 90. Shanghai Tengrui Pharmaceutical Co., Ltd. Business Overview Table 91. Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 93. Shanghai Tengrui Pharmaceutical Co., Ltd. Recent Development Table 94. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Company Information Table 95. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Business Overview Table 96. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 98. Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Recent Development Table 99. Shaanxi Hanwang Pharmaceutical Co., Ltd. Company Information Table 100. Shaanxi Hanwang Pharmaceutical Co., Ltd. Business Overview Table 101. Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 103. Shaanxi Hanwang Pharmaceutical Co., Ltd. Recent Development Table 104. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Company Information Table 105. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Business Overview Table 106. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 108. Jiaozuo Furuitang Pharmaceutical Co., Ltd. Recent Development Table 109. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Company Information Table 110. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Business Overview Table 111. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 113. China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Recent Development Table 114. Hubei Ruihua Pharmaceutical Co., Ltd. Company Information Table 115. Hubei Ruihua Pharmaceutical Co., Ltd. Business Overview Table 116. Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 118. Hubei Ruihua Pharmaceutical Co., Ltd. Recent Development Table 119. Guilin Nanyao Pharmaceutical Co., Ltd. Company Information Table 120. Guilin Nanyao Pharmaceutical Co., Ltd. Business Overview Table 121. Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 123. Guilin Nanyao Pharmaceutical Co., Ltd. Recent Development Table 124. Fujian Dongrui Pharmaceutical Co., Ltd. Company Information Table 125. Fujian Dongrui Pharmaceutical Co., Ltd. Business Overview Table 126. Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 128. Fujian Dongrui Pharmaceutical Co., Ltd. Recent Development Table 129. Diao Group Chengdu Pharmaceutical Co., Ltd. Company Information Table 130. Diao Group Chengdu Pharmaceutical Co., Ltd. Business Overview Table 131. Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 133. Diao Group Chengdu Pharmaceutical Co., Ltd. Recent Development Table 134. Chengdu Hengda Pharmaceutical Co., Ltd. Company Information Table 135. Chengdu Hengda Pharmaceutical Co., Ltd. Business Overview Table 136. Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 138. Chengdu Hengda Pharmaceutical Co., Ltd. Recent Development Table 139. Beijing Taiyang Pharmaceutical Co., Ltd. Company Information Table 140. Beijing Taiyang Pharmaceutical Co., Ltd. Business Overview Table 141. Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 143. Beijing Taiyang Pharmaceutical Co., Ltd. Recent Development Table 144. Anhui Shengying Pharmaceutical Co., Ltd. Company Information Table 145. Anhui Shengying Pharmaceutical Co., Ltd. Business Overview Table 146. Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio Table 148. Anhui Shengying Pharmaceutical Co., Ltd. Recent Development Table 149. Sequent Scientific Company Information Table 150. Sequent Scientific Business Overview Table 151. Sequent Scientific Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Sequent Scientific Antinematode Drugs Product Portfolio Table 153. Sequent Scientific Recent Development Table 154. Salius Pharma Company Information Table 155. Salius Pharma Business Overview Table 156. Salius Pharma Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Salius Pharma Antinematode Drugs Product Portfolio Table 158. Salius Pharma Recent Development Table 159. Lasa Supergenerics Limited Company Information Table 160. Lasa Supergenerics Limited Business Overview Table 161. Lasa Supergenerics Limited Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Lasa Supergenerics Limited Antinematode Drugs Product Portfolio Table 163. Lasa Supergenerics Limited Recent Development Table 164. K.A. Malle Pharmaceuticals Company Information Table 165. K.A. Malle Pharmaceuticals Business Overview Table 166. K.A. Malle Pharmaceuticals Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. K.A. Malle Pharmaceuticals Antinematode Drugs Product Portfolio Table 168. K.A. Malle Pharmaceuticals Recent Development Table 169. Johnson & Johnson Company Information Table 170. Johnson & Johnson Business Overview Table 171. Johnson & Johnson Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 172. Johnson & Johnson Antinematode Drugs Product Portfolio Table 173. Johnson & Johnson Recent Development Table 174. GlaxoSmithKline Company Information Table 175. GlaxoSmithKline Business Overview Table 176. GlaxoSmithKline Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 177. GlaxoSmithKline Antinematode Drugs Product Portfolio Table 178. GlaxoSmithKline Recent Development Table 179. Fredun Pharmaceuticals Ltd Company Information Table 180. Fredun Pharmaceuticals Ltd Business Overview Table 181. Fredun Pharmaceuticals Ltd Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 182. Fredun Pharmaceuticals Ltd Antinematode Drugs Product Portfolio Table 183. Fredun Pharmaceuticals Ltd Recent Development Table 184. Esteve Pharmaceuticals Company Information Table 185. Esteve Pharmaceuticals Business Overview Table 186. Esteve Pharmaceuticals Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 187. Esteve Pharmaceuticals Antinematode Drugs Product Portfolio Table 188. Esteve Pharmaceuticals Recent Development Table 189. Eipico Company Information Table 190. Eipico Business Overview Table 191. Eipico Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 192. Eipico Antinematode Drugs Product Portfolio Table 193. Eipico Recent Development Table 194. Cadila Pharmaceuticals Company Information Table 195. Cadila Pharmaceuticals Business Overview Table 196. Cadila Pharmaceuticals Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 197. Cadila Pharmaceuticals Antinematode Drugs Product Portfolio Table 198. Cadila Pharmaceuticals Recent Development Table 199. Amneal Pharmaceuticals Company Information Table 200. Amneal Pharmaceuticals Business Overview Table 201. Amneal Pharmaceuticals Antinematode Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 202. Amneal Pharmaceuticals Antinematode Drugs Product Portfolio Table 203. Amneal Pharmaceuticals Recent Development Table 204. North America Antinematode Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 205. North America Antinematode Drugs Sales by Country (2021-2026) & (K Units) Table 206. North America Antinematode Drugs Sales Market Share by Country (2021-2026) Table 207. North America Antinematode Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 208. North America Antinematode Drugs Sales Market Share Forecast by Country (2027-2032) Table 209. North America Antinematode Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 210. North America Antinematode Drugs Market Size by Country (2021-2026) & (US$ Million) Table 211. North America Antinematode Drugs Market Share by Country (2021-2026) Table 212. North America Antinematode Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 213. North America Antinematode Drugs Market Share Forecast by Country (2027-2032) Table 214. Europe Antinematode Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 215. Europe Antinematode Drugs Sales by Country (2021-2026) & (K Units) Table 216. Europe Antinematode Drugs Sales Market Share by Country (2021-2026) Table 217. Europe Antinematode Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 218. Europe Antinematode Drugs Sales Market Share Forecast by Country (2027-2032) Table 219. Europe Antinematode Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 220. Europe Antinematode Drugs Market Size by Country (2021-2026) & (US$ Million) Table 221. Europe Antinematode Drugs Market Share by Country (2021-2026) Table 222. Europe Antinematode Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 223. Europe Antinematode Drugs Market Share Forecast by Country (2027-2032) Table 224. Asia-Pacific Antinematode Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 225. Asia-Pacific Antinematode Drugs Sales by Country (2021-2026) & (K Units) Table 226. Asia-Pacific Antinematode Drugs Sales Market Share by Country (2021-2026) Table 227. Asia-Pacific Antinematode Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 228. Asia-Pacific Antinematode Drugs Sales Market Share Forecast by Country (2027-2032) Table 229. Asia-Pacific Antinematode Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 230. Asia-Pacific Antinematode Drugs Market Size by Country (2021-2026) & (US$ Million) Table 231. Asia-Pacific Antinematode Drugs Market Share by Country (2021-2026) Table 232. Asia-Pacific Antinematode Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 233. Asia-Pacific Antinematode Drugs Market Share Forecast by Country (2027-2032) Table 234. Latin America Antinematode Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 235. Latin America Antinematode Drugs Sales by Country (2021-2026) & (K Units) Table 236. Latin America Antinematode Drugs Sales Market Share by Country (2021-2026) Table 237. Latin America Antinematode Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 238. Latin America Antinematode Drugs Sales Market Share Forecast by Country (2027-2032) Table 239. Latin America Antinematode Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 240. Latin America Antinematode Drugs Market Size by Country (2021-2026) & (US$ Million) Table 241. Latin America Antinematode Drugs Market Share by Country (2021-2026) Table 242. Latin America Antinematode Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 243. Latin America Antinematode Drugs Market Share Forecast by Country (2027-2032) Table 244. Middle East and Africa Antinematode Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 245. Middle East and Africa Antinematode Drugs Sales by Country (2021-2026) & (K Units) Table 246. Middle East and Africa Antinematode Drugs Sales Market Share by Country (2021-2026) Table 247. Middle East and Africa Antinematode Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 248. Middle East and Africa Antinematode Drugs Sales Market Share Forecast by Country (2027-2032) Table 249. Middle East and Africa Antinematode Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 250. Middle East and Africa Antinematode Drugs Market Size by Country (2021-2026) & (US$ Million) Table 251. Middle East and Africa Antinematode Drugs Market Share by Country (2021-2026) Table 252. Middle East and Africa Antinematode Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 253. Middle East and Africa Antinematode Drugs Market Share Forecast by Country (2027-2032) Table 254. Key Raw Materials Table 255. Raw Materials Key Suppliers Table 256. Antinematode Drugs Distributors List Table 257. Antinematode Drugs Customers List Table 258. Research Programs/Design for This Report Table 259. Authors List of This Report Table 260. Secondary Sources Table 261. Primary Sources List of Figures Figure 1. Antinematode Drugs Image Figure 2. Global Antinematode Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antinematode Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Antinematode Drugs Sales (2021-2032) & (K Units) Figure 5. Albendazole Image Figure 6. Global Albendazole Sales YoY Growth (2021-2032) & (K Units) Figure 7. Mebendazole Image Figure 8. Global Mebendazole Sales YoY Growth (2021-2032) & (K Units) Figure 9. Piperazine Image Figure 10. Global Piperazine Sales YoY Growth (2021-2032) & (K Units) Figure 11. Pyrantel Pamoate Image Figure 12. Global Pyrantel Pamoate Sales YoY Growth (2021-2032) & (K Units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global Antinematode Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Antinematode Drugs Market Share by Type 2025 VS 2032 Figure 17. North America Antinematode Drugs Sales Market Share in Volume by Type in 2025 Figure 18. North America Antinematode Drugs Sales Market Share in Value by Type in 2025 Figure 19. Europe Antinematode Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Europe Antinematode Drugs Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Antinematode Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Antinematode Drugs Sales Market Share in Value by Type in 2025 Figure 23. Latin America Antinematode Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Antinematode Drugs Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Antinematode Drugs Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Antinematode Drugs Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Antinematode Drugs Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. For Veterinary Use Image Figure 30. Global For Veterinary Use Sales YoY Growth (2021-2032) & (K Units) Figure 31. For Human Use Image Figure 32. Global For Human Use Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global Antinematode Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Antinematode Drugs Market Share by Application 2025 VS 2032 Figure 35. North America Antinematode Drugs Sales Market Share in Volume by Application in 2025 Figure 36. North America Antinematode Drugs Sales Market Share in Value by Application in 2025 Figure 37. Europe Antinematode Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Europe Antinematode Drugs Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Antinematode Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Antinematode Drugs Sales Market Share in Value by Application in 2025 Figure 41. Latin America Antinematode Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Antinematode Drugs Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Antinematode Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Antinematode Drugs Sales Market Share in Value by Application in 2025 Figure 45. North America Antinematode Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America Antinematode Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Antinematode Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Antinematode Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Antinematode Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe Antinematode Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Antinematode Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Antinematode Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Antinematode Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific Antinematode Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Antinematode Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Antinematode Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Antinematode Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America Antinematode Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Antinematode Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Antinematode Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Antinematode Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa Antinematode Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Antinematode Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Antinematode Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Antinematode Drugs Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Antinematode Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Albendazole
  • Mebendazole
  • Piperazine
  • Pyrantel Pamoate
  • Others
Applications
  • For Veterinary Use
  • For Human Use
Companies covered
  • Zhejiang Anbet Pharmaceutical Co., Ltd.
  • Sichuan Tiande Pharmaceutical Co., Ltd.
  • Shaoxing Minsheng Pharmaceutical Co., Ltd.
  • Shanghai Tengrui Pharmaceutical Co., Ltd.
  • Shanghai SPH Xinyi Pharmaceutical Co., Ltd.
  • Shaanxi Hanwang Pharmaceutical Co., Ltd.
  • Jiaozuo Furuitang Pharmaceutical Co., Ltd.
  • China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd.
  • Hubei Ruihua Pharmaceutical Co., Ltd.
  • Guilin Nanyao Pharmaceutical Co., Ltd.
  • Fujian Dongrui Pharmaceutical Co., Ltd.
  • Diao Group Chengdu Pharmaceutical Co., Ltd.
  • Chengdu Hengda Pharmaceutical Co., Ltd.
  • Beijing Taiyang Pharmaceutical Co., Ltd.
  • Anhui Shengying Pharmaceutical Co., Ltd.
  • Sequent Scientific
  • Salius Pharma
  • Lasa Supergenerics Limited
  • K.A. Malle Pharmaceuticals
  • Johnson & Johnson
  • GlaxoSmithKline
  • Fredun Pharmaceuticals Ltd
  • Esteve Pharmaceuticals
  • Eipico
  • Cadila Pharmaceuticals
  • Amneal Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antinematode Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Antinematode Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Antinematode Drugs Market by Type
  6. 1.3.1 Albendazole
  7. 1.3.2 Mebendazole
  8. 1.3.3 Piperazine
  9. 1.3.4 Pyrantel Pamoate
  10. 1.3.5 Others
  11. 1.4 Global Antinematode Drugs Market Size by Type
  12. 1.4.1 Global Antinematode Drugs Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Antinematode Drugs Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Antinematode Drugs Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Antinematode Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Antinematode Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Antinematode Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Antinematode Drugs Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Antinematode Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Antinematode Drugs Industry Trends
  2. 2.2 Antinematode Drugs Industry Drivers
  3. 2.3 Antinematode Drugs Industry Opportunities and Challenges
  4. 2.4 Antinematode Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Antinematode Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Antinematode Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Antinematode Drugs Price (2021-2026)
  4. 3.4 Global Antinematode Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antinematode Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Antinematode Drugs Company, Product Type & Application
  7. 3.7 Global Antinematode Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antinematode Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antinematode Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antinematode Drugs Tier 1, Tier 2, and Tier 3
4 Antinematode Drugs Regional Status and Outlook
  1. 4.1 Global Antinematode Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Antinematode Drugs Historic Market Size by Region
  3. 4.2.1 Global Antinematode Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Antinematode Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Antinematode Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Antinematode Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Antinematode Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Antinematode Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Antinematode Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Antinematode Drugs by Application
  1. 5.1 Antinematode Drugs Market by Application
  2. 5.1.1 For Veterinary Use
  3. 5.1.2 For Human Use
  4. 5.2 Global Antinematode Drugs Market Size by Application
  5. 5.2.1 Global Antinematode Drugs Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Antinematode Drugs Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Antinematode Drugs Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Antinematode Drugs Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Antinematode Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Antinematode Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Antinematode Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Antinematode Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Zhejiang Anbet Pharmaceutical Co., Ltd.
  2. 6.1.1 Zhejiang Anbet Pharmaceutical Co., Ltd. Company Information
  3. 6.1.2 Zhejiang Anbet Pharmaceutical Co., Ltd. Business Overview
  4. 6.1.3 Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Zhejiang Anbet Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  6. 6.1.5 Zhejiang Anbet Pharmaceutical Co., Ltd. Recent Developments
  7. 6.2 Sichuan Tiande Pharmaceutical Co., Ltd.
  8. 6.2.1 Sichuan Tiande Pharmaceutical Co., Ltd. Company Information
  9. 6.2.2 Sichuan Tiande Pharmaceutical Co., Ltd. Business Overview
  10. 6.2.3 Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sichuan Tiande Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  12. 6.2.5 Sichuan Tiande Pharmaceutical Co., Ltd. Recent Developments
  13. 6.3 Shaoxing Minsheng Pharmaceutical Co., Ltd.
  14. 6.3.1 Shaoxing Minsheng Pharmaceutical Co., Ltd. Company Information
  15. 6.3.2 Shaoxing Minsheng Pharmaceutical Co., Ltd. Business Overview
  16. 6.3.3 Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Shaoxing Minsheng Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  18. 6.3.5 Shaoxing Minsheng Pharmaceutical Co., Ltd. Recent Developments
  19. 6.4 Shanghai Tengrui Pharmaceutical Co., Ltd.
  20. 6.4.1 Shanghai Tengrui Pharmaceutical Co., Ltd. Company Information
  21. 6.4.2 Shanghai Tengrui Pharmaceutical Co., Ltd. Business Overview
  22. 6.4.3 Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Shanghai Tengrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  24. 6.4.5 Shanghai Tengrui Pharmaceutical Co., Ltd. Recent Developments
  25. 6.5 Shanghai SPH Xinyi Pharmaceutical Co., Ltd.
  26. 6.5.1 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Company Information
  27. 6.5.2 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Business Overview
  28. 6.5.3 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  30. 6.5.5 Shanghai SPH Xinyi Pharmaceutical Co., Ltd. Recent Developments
  31. 6.6 Shaanxi Hanwang Pharmaceutical Co., Ltd.
  32. 6.6.1 Shaanxi Hanwang Pharmaceutical Co., Ltd. Company Information
  33. 6.6.2 Shaanxi Hanwang Pharmaceutical Co., Ltd. Business Overview
  34. 6.6.3 Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Shaanxi Hanwang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  36. 6.6.5 Shaanxi Hanwang Pharmaceutical Co., Ltd. Recent Developments
  37. 6.7 Jiaozuo Furuitang Pharmaceutical Co., Ltd.
  38. 6.7.1 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Company Information
  39. 6.7.2 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Business Overview
  40. 6.7.3 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  42. 6.7.5 Jiaozuo Furuitang Pharmaceutical Co., Ltd. Recent Developments
  43. 6.8 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd.
  44. 6.8.1 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Company Information
  45. 6.8.2 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Business Overview
  46. 6.8.3 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  48. 6.8.5 China Resources Sanjiu (Beijing) Pharmaceutical Co., Ltd. Recent Developments
  49. 6.9 Hubei Ruihua Pharmaceutical Co., Ltd.
  50. 6.9.1 Hubei Ruihua Pharmaceutical Co., Ltd. Company Information
  51. 6.9.2 Hubei Ruihua Pharmaceutical Co., Ltd. Business Overview
  52. 6.9.3 Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Hubei Ruihua Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  54. 6.9.5 Hubei Ruihua Pharmaceutical Co., Ltd. Recent Developments
  55. 6.10 Guilin Nanyao Pharmaceutical Co., Ltd.
  56. 6.10.1 Guilin Nanyao Pharmaceutical Co., Ltd. Company Information
  57. 6.10.2 Guilin Nanyao Pharmaceutical Co., Ltd. Business Overview
  58. 6.10.3 Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Guilin Nanyao Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  60. 6.10.5 Guilin Nanyao Pharmaceutical Co., Ltd. Recent Developments
  61. 6.11 Fujian Dongrui Pharmaceutical Co., Ltd.
  62. 6.11.1 Fujian Dongrui Pharmaceutical Co., Ltd. Company Information
  63. 6.11.2 Fujian Dongrui Pharmaceutical Co., Ltd. Business Overview
  64. 6.11.3 Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Fujian Dongrui Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  66. 6.11.5 Fujian Dongrui Pharmaceutical Co., Ltd. Recent Developments
  67. 6.12 Diao Group Chengdu Pharmaceutical Co., Ltd.
  68. 6.12.1 Diao Group Chengdu Pharmaceutical Co., Ltd. Company Information
  69. 6.12.2 Diao Group Chengdu Pharmaceutical Co., Ltd. Business Overview
  70. 6.12.3 Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Diao Group Chengdu Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  72. 6.12.5 Diao Group Chengdu Pharmaceutical Co., Ltd. Recent Developments
  73. 6.13 Chengdu Hengda Pharmaceutical Co., Ltd.
  74. 6.13.1 Chengdu Hengda Pharmaceutical Co., Ltd. Company Information
  75. 6.13.2 Chengdu Hengda Pharmaceutical Co., Ltd. Business Overview
  76. 6.13.3 Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Chengdu Hengda Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  78. 6.13.5 Chengdu Hengda Pharmaceutical Co., Ltd. Recent Developments
  79. 6.14 Beijing Taiyang Pharmaceutical Co., Ltd.
  80. 6.14.1 Beijing Taiyang Pharmaceutical Co., Ltd. Company Information
  81. 6.14.2 Beijing Taiyang Pharmaceutical Co., Ltd. Business Overview
  82. 6.14.3 Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Beijing Taiyang Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  84. 6.14.5 Beijing Taiyang Pharmaceutical Co., Ltd. Recent Developments
  85. 6.15 Anhui Shengying Pharmaceutical Co., Ltd.
  86. 6.15.1 Anhui Shengying Pharmaceutical Co., Ltd. Company Information
  87. 6.15.2 Anhui Shengying Pharmaceutical Co., Ltd. Business Overview
  88. 6.15.3 Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Anhui Shengying Pharmaceutical Co., Ltd. Antinematode Drugs Product Portfolio
  90. 6.15.5 Anhui Shengying Pharmaceutical Co., Ltd. Recent Developments
  91. 6.16 Sequent Scientific
  92. 6.16.1 Sequent Scientific Company Information
  93. 6.16.2 Sequent Scientific Business Overview
  94. 6.16.3 Sequent Scientific Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Sequent Scientific Antinematode Drugs Product Portfolio
  96. 6.16.5 Sequent Scientific Recent Developments
  97. 6.17 Salius Pharma
  98. 6.17.1 Salius Pharma Company Information
  99. 6.17.2 Salius Pharma Business Overview
  100. 6.17.3 Salius Pharma Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Salius Pharma Antinematode Drugs Product Portfolio
  102. 6.17.5 Salius Pharma Recent Developments
  103. 6.18 Lasa Supergenerics Limited
  104. 6.18.1 Lasa Supergenerics Limited Company Information
  105. 6.18.2 Lasa Supergenerics Limited Business Overview
  106. 6.18.3 Lasa Supergenerics Limited Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Lasa Supergenerics Limited Antinematode Drugs Product Portfolio
  108. 6.18.5 Lasa Supergenerics Limited Recent Developments
  109. 6.19 K.A. Malle Pharmaceuticals
  110. 6.19.1 K.A. Malle Pharmaceuticals Company Information
  111. 6.19.2 K.A. Malle Pharmaceuticals Business Overview
  112. 6.19.3 K.A. Malle Pharmaceuticals Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 K.A. Malle Pharmaceuticals Antinematode Drugs Product Portfolio
  114. 6.19.5 K.A. Malle Pharmaceuticals Recent Developments
  115. 6.20 Johnson & Johnson
  116. 6.20.1 Johnson & Johnson Company Information
  117. 6.20.2 Johnson & Johnson Business Overview
  118. 6.20.3 Johnson & Johnson Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Johnson & Johnson Antinematode Drugs Product Portfolio
  120. 6.20.5 Johnson & Johnson Recent Developments
  121. 6.21 GlaxoSmithKline
  122. 6.21.1 GlaxoSmithKline Company Information
  123. 6.21.2 GlaxoSmithKline Business Overview
  124. 6.21.3 GlaxoSmithKline Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 GlaxoSmithKline Antinematode Drugs Product Portfolio
  126. 6.21.5 GlaxoSmithKline Recent Developments
  127. 6.22 Fredun Pharmaceuticals Ltd
  128. 6.22.1 Fredun Pharmaceuticals Ltd Company Information
  129. 6.22.2 Fredun Pharmaceuticals Ltd Business Overview
  130. 6.22.3 Fredun Pharmaceuticals Ltd Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Fredun Pharmaceuticals Ltd Antinematode Drugs Product Portfolio
  132. 6.22.5 Fredun Pharmaceuticals Ltd Recent Developments
  133. 6.23 Esteve Pharmaceuticals
  134. 6.23.1 Esteve Pharmaceuticals Company Information
  135. 6.23.2 Esteve Pharmaceuticals Business Overview
  136. 6.23.3 Esteve Pharmaceuticals Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 Esteve Pharmaceuticals Antinematode Drugs Product Portfolio
  138. 6.23.5 Esteve Pharmaceuticals Recent Developments
  139. 6.24 Eipico
  140. 6.24.1 Eipico Company Information
  141. 6.24.2 Eipico Business Overview
  142. 6.24.3 Eipico Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 Eipico Antinematode Drugs Product Portfolio
  144. 6.24.5 Eipico Recent Developments
  145. 6.25 Cadila Pharmaceuticals
  146. 6.25.1 Cadila Pharmaceuticals Company Information
  147. 6.25.2 Cadila Pharmaceuticals Business Overview
  148. 6.25.3 Cadila Pharmaceuticals Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  149. 6.25.4 Cadila Pharmaceuticals Antinematode Drugs Product Portfolio
  150. 6.25.5 Cadila Pharmaceuticals Recent Developments
  151. 6.26 Amneal Pharmaceuticals
  152. 6.26.1 Amneal Pharmaceuticals Company Information
  153. 6.26.2 Amneal Pharmaceuticals Business Overview
  154. 6.26.3 Amneal Pharmaceuticals Antinematode Drugs Sales, Revenue and Gross Margin (2021-2026)
  155. 6.26.4 Amneal Pharmaceuticals Antinematode Drugs Product Portfolio
  156. 6.26.5 Amneal Pharmaceuticals Recent Developments
7 North America by Country
  1. 7.1 North America Antinematode Drugs Sales by Country
  2. 7.1.1 North America Antinematode Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Antinematode Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Antinematode Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Antinematode Drugs Market Size by Country
  6. 7.2.1 North America Antinematode Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Antinematode Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Antinematode Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Antinematode Drugs Sales by Country
  2. 8.1.1 Europe Antinematode Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Antinematode Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Antinematode Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Antinematode Drugs Market Size by Country
  6. 8.2.1 Europe Antinematode Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Antinematode Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Antinematode Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Antinematode Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Antinematode Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Antinematode Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Antinematode Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Antinematode Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Antinematode Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Antinematode Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Antinematode Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Antinematode Drugs Sales by Country
  2. 10.1.1 South America Antinematode Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Antinematode Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Antinematode Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Antinematode Drugs Market Size by Country
  6. 10.2.1 South America Antinematode Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Antinematode Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Antinematode Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Antinematode Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Antinematode Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Antinematode Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Antinematode Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Antinematode Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Antinematode Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Antinematode Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Antinematode Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Antinematode Drugs Value Chain Analysis
  2. 12.1.1 Antinematode Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Antinematode Drugs Production Mode & Process
  7. 12.2 Antinematode Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Antinematode Drugs Distributors
  10. 12.2.3 Antinematode Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst